Design and setting: Cohort study of 158 Indigenous and 152 non-Indigenous patients (frequency-matched on age, sex and rurality) diagnosed with lung cancer between 1996 and 2002 and treated in Queensland public hospitals.
Results: Survival of Indigenous lung cancer patients was significantly lower than that of non-Indigenous patients (median survival, 4.3 v 10.3 months; hazard ratio, 1.48; 95% CI, 1.14–1.92). Of 158 Indigenous patients, 72 (46%) received active treatment with chemotherapy, radiotherapy or surgery compared with 109 (72%) of the 152 non-Indigenous patients, and this treatment disparity remained after adjusting for histological subtype, stage at diagnosis, and comorbidities (adjusted risk ratio, 0.65; 95% CI, 0.53–0.73). The treatment disparity explained most of the survival deficit: the hazard ratio reduced to 1.10 (95% CI, 0.83–1.44) after inclusion of treatment variables in the proportional hazards survival model. The remaining survival deficit was explained by the higher prevalence of comorbidities among Indigenous cancer patients, mainly diabetes.
- 1. South Australian Cancer Registry. Cancer incidence, mortality and case survival in the South Australian Aboriginal population. In: Epidemiology of cancer in South Australia 1977 to 1996. Adelaide: South Australian Health Commission, 1997.
- 2. Coory M, Thompson A, Ganguly I. Cancer among people living in rural and remote Indigenous communities. Med J Aust 2000; 173: 301-304.
- 3. Condon J, Armstrong B, Barnes A, Cunningham J. Cancer in Indigenous Australians: a review. Cancer Causes Control 2003; 14: 109-121.
- 4. Australian Bureau of Statistics, Australian Institute of Health and Welfare. The health and welfare of Australia’s Aboriginal and Torres Strait Islander Peoples 2005. Canberra: ABS, 2005. (ABS Cat. No. 4704.0.)
- 5. Condon J, Armstrong B, Barnes T, Zhao Y. Cancer incidence and survival for Indigenous Australians in the Northern Territory. Aust N Z J Public Health 2005; 29: 123-128.
- 6. Valery P, Coory M, Stirling J, Green A. Cancer diagnosis, treatment and survival in Indigenous compared with non-Indigenous Australians treated in public hospitals. Lancet 2006; 367: 1842-1848.
- 7. Australian Government Department of Health and Aged Care. Accessibility/Remoteness Index of Australia. Canberra: DHAC, 1999.
- 8. Rothman K, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998.
- 9. Surveillance Epidemiology and End Results. Summary staging manual 2000: codes and coding instructions. Bethesda: National Cancer Institute, 2001.
- 10. Condon JR, Cunningham J, Barnes T, et al. Cancer diagnosis and treatment in the Northern Territory: assessing health service performance for indigenous Australians. Intern Med J 2006; 36: 498-505.
- 11. National Health and Medical Research Council. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Canberra: NHMRC, 2004.
- 12. Greenwald HP, Polissar NL, Borgatta EF, et al. Social factors, treatment, and survival in early-stage non-small cell lung cancer. Am J Public Health 1998; 88: 1681-1684.
- 13. Bach P, Schrag D, Brawley O, et al. Survival of blacks and whites after a cancer diagnosis. JAMA 2002; 287: 2106-2113.
- 14. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341: 1198-1205.
- 15. Hall S, Bulsara C, Bulsara M, et al. Treatment patterns for cancer in Western Australia: does being Indigenous make a difference? Med J Aust 2004; 181: 191-194. <MJA full text>
- 16. Janssen-Heijnen M, Gatta G, Forman D, et al; Eurocare Working Group. Variation in survival of patients with lung cancer in Europe 1985–1989. Eur J Cancer 1998; 34: 2191-2196.
- 17. Earle C, Neuman P, Gelber R. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002; 20: 1786-1792.
- 18. Coote A. Prevention rather than cure. Making the case for choosing health. London: King’s Fund Publications, 2004.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.